
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$102.94M
Market Cap
-
P/E Ratio
-40.46
EPS
$34.27
52 Week High
$3.60
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $40M |
| Total Revenue | $57M |
| Cost Of Revenue | $17M |
| Costof Goods And Services Sold | $17M |
| Operating Income | -$83M |
| Selling General And Administrative | $119M |
| Research And Development | $9.6M |
| Operating Expenses | $123M |
| Investment Income Net | - |
| Net Interest Income | -$2M |
| Interest Income | - |
| Interest Expense | $2M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4M |
| Income Before Tax | -$73M |
| Income Tax Expense | -$1K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$73M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$71M |
| Ebitda | -$67M |
| Net Income | -$73M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $40M |
| Total Revenue | $57M |
| Cost Of Revenue | $17M |
| Costof Goods And Services Sold | $17M |
| Operating Income | -$83M |
| Selling General And Administrative | $119M |
| Research And Development | $9.6M |
| Operating Expenses | $123M |
| Investment Income Net | - |
| Net Interest Income | -$2M |
| Interest Income | - |
| Interest Expense | $2M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4M |
| Income Before Tax | -$73M |
| Income Tax Expense | -$1K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$73M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$71M |
| Ebitda | -$67M |
| Net Income | -$73M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Scilex Holding Company is a biopharmaceutical innovator based in Palo Alto, California, focused on the development and commercialization of non-opioid therapeutics for acute and chronic pain management. With a strong commitment to improving patient outcomes and reducing opioid dependency, Scilex leverages advanced research and development to create effective pain relief solutions that meet the evolving needs of healthcare providers and patients alike. The company is positioned to play a pivotal role in transforming the pain management landscape, offering alternative options that enhance quality of life for individuals suffering from debilitating pain.